Clinical Trial

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Name: A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) — clinical trial record (NCT06533098)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FREESIA-3

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Trial Details

NCT Number	NCT06533098
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Thrombocytopenia, Neonatal Alloimmune
Enrollment	50 participants
Start Date	2025-02-10
Primary Completion	2027-12-15 (estimated)
Study Completion	2029-12-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-06